From STAT’s Adam Feuerstein: The FDA informed Capricor Therapeutics that a meeting of outside experts will be convened to ...

The CHMP recommends conditional marketing authorization for Duvyzat to treat Duchenne muscular dystrophy in patients aged 6 ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular ...

Uncertainty around ELEVIDYS sales impact Sarepta Therapeutics, Inc. Click here to find out why I downgraded SRPT stock to a ...

Sarepta has submitted a request to the FDA to include the death case in Elevidys’ label, and the agency plans to review the ...

Capricor Therapeutics saw its shares fall 13% by the end of trading Monday as its investigational cell therapy deramiocel for ...

9 The period of treatment was twelve months ... He believed that the underlying molecular defect in Duchenne muscular dystrophy was affected by physical activity which hastened the deterioration ...

MEDFORD, Ore.- A fundraiser held at the Children’s Museum of Southern Oregon raises thousands of dollars to help a local boy ...

Duchenne muscular dystrophy (DMD) in India faces challenges in diagnosis, treatment, and support, highlighting the urgent ...

Alvin Luk, CEO of HuidaGene, is using his experience in big pharma to lead the small Shanghai and New Jersey-based biotech on ...

Cas12Max-based gene editing therapy for Duchenne muscular dystrophy, one of the most severe forms of the inherited muscular dystrophies that affects primarily boys. Huidagene Therapeutics and ...